Role of Eotaxin-1 Signaling in Ovarian Cancer

Purpose: Tumor cell growth and migration can be directly regulated by chemokines. In the present study, the association of CCL11 with ovarian cancer has been investigated. Experimental Design and Results: Circulating levels of CCL11 in sera of patients with ovarian cancer were significantly lower than those in healthy women or women with breast, lung, liver, pancreatic, or colon cancer. Cultured ovarian carcinoma cells absorbed soluble CCL11, indicating that absorption by tumor cells could be responsible for the observed reduction of serum level of CCL11 in ovarian cancer. Postoperative CCL11 levels in women with ovarian cancer negatively correlated with relapse-free survival. Ovarian tumors overexpressed three known cognate receptors of CCL11, CC chemokine receptors (CCR) 2, 3, and 5. Strong positive correlation was observed between expression of individual receptors and tumor grade. CCL11 potently stimulated proliferation and migration/invasion of ovarian carcinoma cell lines, and these effects were inhibited by neutralizing antibodies against CCR2, CCR3, and CCR5. The growth-stimulatory effects of CCL11 were likely associated with activation of extracellular signal-regulated kinase 1/2, MEK1, and STAT3 phosphoproteins and with increased production of multiple cytokines, growth factors, and angiogenic factors. Inhibition of CCL11 signaling by the combination of neutralizing antibodies against the ligand and its receptors significantly increased sensitivity to cisplatin in ovarian carcinoma cells. Conclusion: We conclude that CCL11 signaling plays an important role in proliferation and invasion of ovarian carcinoma cells and CCL11 pathway could be targeted for therapy in ovarian cancer. Furthermore, CCL11 could be used as a biomarker and a prognostic factor of relapse-free survival in ovarian cancer.

[1]  D. Taub,et al.  Chemokines and T lymphocyte activation: I. Beta chemokines costimulate human T lymphocyte activation in vitro. , 1996, Journal of immunology.

[2]  R. Negus.  The Chemokines: Cytokines that Direct Leukocyte Migration , 1996, Journal of the Royal Society of Medicine.

[3]  Xingchen Du,et al.  Role of CXCL12 in metastasis of human ovarian cancer , 2007, Chinese medical journal.

[4]  T. Godfrey,et al.  Chemokine receptors 6 and 7 identify a metastatic expression pattern in squamous cell carcinoma of the head and neck. , 2005, Advances in oto-rhino-laryngology.

[5]  I. Ghobrial,et al.  Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. , 2004, Mayo Clinic proceedings.

[6]  S. Hwang,et al.  Chemokines, chemokine receptors, and cancer metastasis , 2006, Journal of leukocyte biology.

[7]  P. Leder,et al.  Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia , 1996, Nature Medicine.

[8]  R. Clarke,et al.  The p160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine/paracrine activity of SDF-1alpha/CXCL12. , 2005, Carcinogenesis.

[9]  G. Stamp,et al.  Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. , 1997, The American journal of pathology.

[10]  E. Fish,et al.  Chemokines and cancer. , 2005, Cancer treatment and research.

[11]  J. Berek,et al.  Ovarian cancer: epidemiology, biology, and prognostic factors. , 2000, Seminars in surgical oncology.

[12]  A. Lokshin,et al.  Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. , 2003, Cancer letters.

[13]  G. Johnson,et al.  MEK-1 phosphorylation by MEK kinase, Raf, and mitogen-activated protein kinase: analysis of phosphopeptides and regulation of activity. , 1994, Molecular biology of the cell.

[14]  S. Stafford,et al.  Eotaxin induces degranulation and chemotaxis of eosinophils through the activation of ERK2 and p38 mitogen-activated protein kinases. , 2000, Blood.

[15]  P. Leder,et al.  Constitutive and allergen-induced expression of eotaxin mRNA in the guinea pig lung , 1995, The Journal of experimental medicine.

[16]  M. Rothenberg,et al.  CC Chemokine Receptor-3 Undergoes Prolonged Ligand-induced Internalization* , 1999, The Journal of Biological Chemistry.

[17]  C. Bertrand,et al.  CCR3 blockade as a new therapy for asthma , 2000, Expert opinion on investigational drugs.

[18]  T. Williams,et al.  The CC Chemokine Eotaxin (CCL11) Is a Partial Agonist of CC Chemokine Receptor 2b* , 2001, The Journal of Biological Chemistry.

[19]  H. Sakurai,et al.  Role of the CXCL12/CXCR4 axis in peritoneal carcinomatosis of gastric cancer. , 2006, Cancer research.

[20]  M. Piver,et al.  Etiology, biology, and epidemiology of ovarian cancer. , 1994, Seminars in surgical oncology.

[21]  J. Ward,et al.  Eotaxin (CCL11) Induces In Vivo Angiogenic Responses by Human CCR3+ Endothelial Cells1 , 2001, The Journal of Immunology.

[22]  G. Milligan,et al.  Allosteric modulation of heterodimeric G-protein-coupled receptors. , 2007, Trends in pharmacological sciences.

[23]  G. M. Fischer,et al.  STAT3 activation, chemokine receptor expression, and cyclin-Cdk function in B-1 cells. , 2000, Current topics in microbiology and immunology.

[24]  A. Huvos,et al.  Messenger RNA Expression Levels of CXCR4 Correlate with Metastatic Behavior and Outcome in Patients with Osteosarcoma , 2005, Clinical Cancer Research.

[25]  Xiao-Hua Wu,et al.  Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. , 2006, Gynecologic oncology.

[26]  Kazuhiko Yamamoto,et al.  Regulation of Human Eotaxin Generation by Th1-/Th2-Derived Cytokines , 2000, International Archives of Allergy and Immunology.

[27]  S. McColl,et al.  Chemokine networks in vivo: involvement of C-X-C and C-C chemokines in neutrophil extravasation in vivo in response to TNF-alpha. , 1997, Journal of immunology.

[28]  Xiyun Deng,et al.  CXCL12/CXCR4 signaling activates Akt‐1 and MMP‐9 expression in prostate cancer cells: The role of bone microenvironment‐associated CXCL12 , 2006, The Prostate.

[29]  H. Broxmeyer,et al.  Blocking of c-FLIP(L)--independent cycloheximide-induced apoptosis or Fas-mediated apoptosis by the CC chemokine receptor 9/TECK interaction. , 2001, Blood.

[30]  Barbara Foster,et al.  Detection of Intracellular Cytokines by Flow Cytometry , 2002, Current protocols in immunology.

[31]  M. Baggiolini.  Chemokines and Cancer , 1999, Nature Medicine.

[32]  S. Brand,et al.  Cell differentiation dependent expressed CCR6 mediates ERK‐1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells , 2006, Journal of cellular biochemistry.

[33]  A. Luster,et al.  Role of the monocyte chemoattractant protein and eotaxin subfamily of chemokines in allergic inflammation , 1997, Journal of leukocyte biology.

[34]  S. Brand,et al.  CXCR4 and CXCL12 are inversely expressed in colorectal cancer cells and modulate cancer cell migration, invasion and MMP-9 activation. , 2005, Experimental cell research.

[35]  A. Sodhi,et al.  Monocyte chemoattractant protein-1-induced activation of p42/44 MAPK and c-Jun in murine peritoneal macrophages: a potential pathway for macrophage activation. , 2002, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[36]  D. Taub,et al.  β Chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production , 1996, Journal of leukocyte biology.

[37]  M. Brummet,et al.  Functional analysis of the chemokine receptor CCR3 on airway epithelial cells. , 2003, Journal of immunology.

[38]  F. Balkwill,et al.  Chemokine stimulation of monocyte matrix metalloproteinase‐9 requires endogenous TNF‐α  , 2002, European journal of immunology.

[39]  S. Natsugoe,et al.  Expression of CXCL12 and its receptor CXCR4 correlates with lymph node metastasis in submucosal esophageal cancer , 2008, Journal of surgical oncology.

[40]  A. Lokshin,et al.  Multiple effects of TRAIL in human carcinoma cells: induction of apoptosis, senescence, proliferation, and cytokine production. , 2008, Experimental cell research.

[41]  T. Soderling,et al.  Phosphorylation of CBP Mediates Transcriptional Activation by Neural Activity and CaM Kinase IV , 2002, Neuron.

[42]  K. Harshman,et al.  CCR5 Expression Influences the Progression of Human Breast Cancer in a p53-dependent Manner , 2003, The Journal of experimental medicine.

[43]  R. Clarke,et al.  The p 160 family coactivators regulate breast cancer cell proliferation and invasion through autocrine / paracrine activity of SDF-1 a / CXCL 12 , 2005 .

[44]  D. Galson,et al.  Monocyte chemotactic protein‐1 (MCP‐1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion , 2006, The Prostate.

[45]  K. Sakamoto,et al.  βc Cytokine Receptor-Induced Stimulation of cAMP Response Element Binding Protein Phosphorylation Requires Protein Kinase C In Myeloid Cells: A Novel Cytokine Signal Transduction Cascade1 , 2001, The Journal of Immunology.

[46]  C. Garlanda,et al.  Reduced tumorigenicity and augmented leukocyte infiltration after monocyte chemotactic protein-3 (MCP-3) gene transfer: perivascular accumulation of dendritic cells in peritumoral tissue and neutrophil recruitment within the tumor. , 1998, Journal of immunology.

[47]  A. Zlotnik,et al.  The chemokine and chemokine receptor superfamilies and their molecular evolution , 2006, Genome Biology.

[48]  I. Takanami.  Overexpression of CCR7 mRNA in nonsmall cell lung cancer: Correlation with lymph node metastasis , 2003, International journal of cancer.

[49]  J. Rockstroh,et al.  Maraviroc, risks and benefits: a review of the clinical literature. , 2008, Expert opinion on drug safety.

[50]  A. Schecter,et al.  epidermal growth factor receptor , 2005 .

[51]  C. Combadière,et al.  Cloning and Functional Expression of a Human Eosinophil CC Chemokine Receptor (*) , 1995, The Journal of Biological Chemistry.

[52]  Kathryn E Luker,et al.  Functions of CXCL12 and CXCR4 in breast cancer. , 2006, Cancer letters.

[53]  A. Mallet,et al.  IL-4 induces eotaxin: a possible mechanism of selective eosinophil recruitment in helminth infection and atopy. , 1998, Journal of immunology.

[54]  J. Friedland,et al.  Chemokines and their receptors in respiratory disease: a therapeutic target for respiratory syncytial virus infection , 2007, Expert review of anti-infective therapy.

[55]  F. Wamunyokoli,et al.  A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. , 2006, Cancer research.

[56]  B. Rollins,et al.  Inflammatory chemokines in cancer growth and progression. , 2006, European journal of cancer.

[57]  W Newman,et al.  Cloning of the human eosinophil chemoattractant, eotaxin. Expression, receptor binding, and functional properties suggest a mechanism for the selective recruitment of eosinophils. , 1996, The Journal of clinical investigation.

[58]  L. Salamonsen,et al.  Expression of the Chemokine Eotaxin and Its Receptor, CCR3, in Human Endometrium1 , 2000, Biology of reproduction.

[59]  Q. Hamid,et al.  Human monocyte chemoattractant protein (MCP)-4 is a novel CC chemokine with activities on monocytes, eosinophils, and basophils induced in allergic and nonallergic inflammation that signals through the CC chemokine receptors (CCR)-2 and -3. , 1996, Journal of immunology.

[60]  F. Graziano,et al.  Cytokines, chemokines, RANTES, and eotaxin. , 1999, Allergy and asthma proceedings.

[61]  S. Rankin,et al.  Eotaxin and eosinophil recruitment: implications for human disease. , 2000, Molecular medicine today.

[62]  B. Sipos,et al.  The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver. , 2006, Cancer research.

[63]  J. Norgauer,et al.  Overexpression of CXC-chemokines and CXC-chemokine receptor type II constitute an autocrine growth mechanism in the epidermoid carcinoma cells KB and A431. , 1999, Oncology reports.

[64]  A. Lokshin,et al.  Multiple biomarker panels for early detection of ovarian cancer. , 2006, Future oncology.

[65]  J. Wheeler,et al.  Assessing Theoretical Risk and Benefit suggested by Genetic Association Studies of CCR5: Experience in a Drug Development Programme for Maraviroc , 2007, Antiviral therapy.

[66]  M. Peck,et al.  A Small Molecule Antagonist of Chemokine Receptors CCR1 and CCR3 , 2000, The Journal of Biological Chemistry.

[67]  D. Vestweber,et al.  Molecular mechanisms that control leukocyte extravasation: the selectins and the chemokines. , 1999, Histochemistry and cell biology.

[68]  J. Vieira,et al.  Expression and function of the che mokine receptor CCR 7 in thyroid carcinomas , 2006 .

[69]  K. Lamberth,et al.  CCR3 Expression Induced by IL-2 and IL-4 Functioning as a Death Receptor for B Cells1 , 2003, The Journal of Immunology.

[70]  D. Peehl,et al.  Expression of CCL5 (RANTES) and CCR5 in prostate cancer , 2006, The Prostate.

[71]  J. Vieira,et al.  Expression and function of the chemokine receptor CCR7 in thyroid carcinomas. , 2006, The Journal of endocrinology.

[72]  R. Greil,et al.  Up-Regulation of Functional Chemokine Receptor CCR3 in Human Renal Cell Carcinoma , 2005, Clinical Cancer Research.

[73]  M. Probst-Kepper,et al.  CXCR4/CXCL12 expression and signalling in kidney cancer , 2002, British Journal of Cancer.

[74]  J. Demartino,et al.  Cloning, expression, and characterization of the human eosinophil eotaxin receptor , 1996, The Journal of experimental medicine.

[75]  Z. Hall.  Cancer , 1906, The Hospital.

[76]  P. Galle,et al.  Effect of Chemokine Receptors CXCR4 and CCR7 on the Metastatic Behavior of Human Colorectal Cancer , 2005, Clinical Cancer Research.

[77]  M. Baggiolini,et al.  Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. , 2001, Blood.